Revance Therapeutics (NASDAQ:RVNC – Get Rating) had its target price hoisted by HC Wainwright from $42.00 to $48.00 in a research note issued to investors on Wednesday morning, The Fly reports. Several other equities analysts also recently commented on RVNC. StockNews.com upgraded Revance Therapeutics from a sell rating to a hold rating in a research […]
Revance Therapeutics (NASDAQ:RVNC – Get Rating) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.01, Briefing.com reports. The firm had revenue of $49.33 million for the quarter, compared to analysts’ expectations of $46.21 million. Revance Therapeutics had […]
Revance Therapeutics (NASDAQ:RVNC – Get Rating) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.01, Briefing.com reports. Revance Therapeutics had a negative return on equity of 786.70% and a negative net margin of 268.87%. The firm had revenue of […]
Revance Therapeutics (NASDAQ:RVNC – Get Rating) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.01, Briefing.com reports. Revance Therapeutics had a negative net margin of 268.87% and a negative return on equity of 786.70%. The firm had revenue of $49.33 […]
Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) reached a new 52-week high on Monday . The stock traded as high as $36.65 and last traded at $36.60, with a volume of 1859741 shares traded. The stock had previously closed at $34.61. Wall Street Analysts Forecast Growth A number of research analysts recently commented […]